Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P05231 (interleukin-6)
 23,907 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present study was performed on primary cultures of mouse astrocytes and cultures of rat pheochromocytoma PC-12 in order to investigate the regulation of the prion protein (PrP) gene expression in relation to proliferation and differentiation. Treatment of PC-12 cells with interleukin-6 (IL-6) and beta-nerve growth factor (NGF) resulted in induction of neuronal differentiation. Northern blot analysis demonstrated a 4-fold increase of PrP mRNA in relation to cellular differentiation, after 7 days of treatment with either of the two factors. In astrocytes, PrP and glial fibrillary acidic protein (GFAP) mRNA levels were found to be regulated in a similar manner during development in vitro. A 3-fold increase of their mRNAs was observed from 5 to 14 days of culture (proliferation period). Then, their gene expressions showed a slight decrease from 14 to 28 days (maturation period). Treatment of astrocytes with IL-6, basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) appeared to markedly down-regulate the expression of GFAP mRNAs, which might reflect cell maturation. In contrast, they had no significant effect on the expression of PrP gene. These results suggest that the PrP gene expression is differently regulated in neural cells. In neuronal cells, it is mainly associated with differentiation. On the other hand, in astrocytes, the PrP mRNA level seems to be not only related to the proliferation and differentiation stages.
 ...
PMID:Modulation of prion protein gene expression by growth factors in cultured mouse astrocytes and PC-12 cells. 791 3

Clusterin is an authentic Sertoli cell secretory product initially identified in the ram and rat testis. Subsequent studies have shown that this protein is present in almost all organs and in multiple species. Its mRNA increases in the brain undergoing degeneration as a result of infection, brain injury, and other pathological conditions such as Alzheimer's disease. However, its site(s) of synthesis and modulator(s) in the brain are not known. The objectives of this study were to determine if astrocytes could synthesize and secrete clusterin in vitro and to investigate the effects of various cytokines on the secretion and the mRNA expression of clusterin in the primary cultures of astrocytes. Astrocytes were isolated from cerebral cortices of neonatal rats and enriched to a purity of greater than 95% as judged by immunocytochemical staining using antibody against glial fibrillary acidic protein (GFAP), a specific marker of astrocytes. Using immunoprecipitation techniques, we have demonstrated that astrocytes actively synthesize and secrete clusterin in vitro. Immunocytochemical staining using a monospecific antibody against clusterin showed that this protein is localized in the entire cytoplasm and the processes of astrocytes. Treatment of astrocytes with either interleukin-1 beta, or interleukin-2, induced a significant increase in the production and the mRNA levels of clusterin, whereas other cytokines including interleukin-3, interleukin-6, and interferon-gamma had no apparent effect. The results of this study suggest that clusterin may be a marker to study the immune response in the brain.
 ...
PMID:Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. 808 21

Tumor necrosis factor-alpha (TNF-alpha), a cytokine produced by astrocytes in vivo and in vitro, was tested for its effects on two malignant astrocytoma cell lines (A-172, U-87). Both lines were immunoreactive for glial fibrillary acidic protein, vimentin, Class I antigens, and interleukin-6. The lines differed in their expression of Class II and intercellular adhesion molecule-1 (ICAM-1) antigenic determinants: A-172 cells were negative for both Class II and ICAM-1 antigens, while U-87 cells were intensely positive for Class II and weakly positive for ICAM-1. When these astrocytoma cell lines were exposed to TNF-alpha, A-172 growth was stimulated while U-87 growth was inhibited. Furthermore, in U-87 cells, TNF-alpha enhanced both ICAM-1 and interleukin-1 beta (IL-1 beta) expression, and decreased immunoreactivity for transforming growth factor-beta (TGF-beta) protein. In contrast, in the presence of TNF-alpha, A-172 cells remained negative for IL-1 beta and TGF-beta, but showed an increased expression of ICAM-1. These results demonstrate that TNF-alpha can induce changes in growth rate, cytokine production, and surface antigen expression in malignant astrocytomas; however, the nature of these changes is dependent on the specific characteristics of these malignant astrocytomas. The resultant variability in the immunological microenvironment of these tumors may reflect differences in their growth potential.
 ...
PMID:Differential effects of tumor necrosis factor-alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. 809 40

The serum-free mouse embryo (SFME) cell line, derived in serum-free medium from 16-day-old mouse embryos, exhibits unique properties. SFME cells grow indefinitely in culture without senescence, require epidermal growth factor (EGF) or fibroblast growth factor (FGF) for survival and are growth-inhibited by serum. The cell line expresses glial fibrillary acidic protein (GFAP) in response to transforming growth factor beta or serum and cells with similar properties can be isolated directly from brain. Culture of SFME cells with leukemia inhibitory factor (LIF), a peptide implicated in neural tissue development, also resulted in expression of GFAP. Other peptides that share signal transduction mechanisms with LIF--ciliary neurotropic factor, oncostatin M and interleukin-6--also caused expression of GFAP in these cells. These effects were inhibited by concentrations of EGF or FGF that promoted rapid cell growth.
 ...
PMID:Regulation of glial fibrillary acidic protein in serum-free mouse embryo (SFME) cells by leukemia inhibitory factor and related peptides. 829 24

The cytokine interleukin-6 (IL-6) may be a contributing mediator of CNS injury in several neurological disorders. To investigate the role of IL-6 in memory-related disorders, we examined transgenic mice (GFAP-IL6) with cerebral overexpression of IL-6 using paired-pulse facilitation, paired-pulse inhibition, and long-term potentiation (LTP) in an in vitro preparation. We found that paired-pulse potentiation and inhibition in the dentate gyrus of hippocampal slices prepared from the GFAP-IL6 mice did not differ significantly from age-matched control animals, suggesting that the increase in paired-pulse inhibition seen previously in in vivo studies of this model was due to alterations of afferents from other brain regions. However, LTP in the dentate was significantly reduced in slices from GFAP-IL6 transgenic mice when compared with littermate wild-type controls, providing support for a role of IL-6 in the pathogenesis of neurodegenerative associated memory-related disorders.
 ...
PMID:Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. 859 50

Astrocytes respond vigorously to diverse neurological insults. It is still not clear, however, whether this response is stereotypic following different insults or varies according to the injury. We have used a novel immunocytochemical marker of reactive astrocytes, termed M22, together with antibodies to glial fibrillary acidic protein (GFAP), to analyze region- and insult-specific differences in reactive astrocytosis in the murine central nervous system (CNS). Pathology was variously induced by (1) infectious agents, (2) transgenic overexpression of a viral glycoprotein or cytokine, or (3) focal trauma. Scrapie infection induced high levels of both GFAP and M22 epitope expression by hippocampal reactive astrocytes, but neither scrapie nor wild mouse retrovirus infection induced detectable M22 staining in reactive astrocytes of the caudal brain. Focal trauma and human immunodeficiency virus gp120 overexpression induced M22 expression only in the hippocampus, while interleukin-6 overexpression induced it in cerebellar astrocytes. Although M22 expression was limited to areas with extensive damage, GFAP expression was induced in every region of the mouse brain displaying pathology. Staining of routinely fixed human brain tissue demonstrated that M22 also labeled reactive astrocytes in chronic human CNS disease. The restriction of M22 expression to areas of strongly GFAP-positive astrocytosis suggests that the M22 antibody identified highly activated reactive astrocytes. Because of this selective staining of activated astrocytes, the M22 antibody may provide neuropathologists with a good marker for qualitative analysis of the astrocytic response to different injuries.
 ...
PMID:The M22 antibody identifies highly activated reactive astrocytes responding to central nervous system disease. 883 43

The pathogenesis of inflammatory demyelinating diseases of the central nervous system (CNS) is complex and in part reflects the contribution of multiple cellular and molecular factors. Determining whether these factors are primary or secondary to lesion development or are pathogenic versus protective or reparative represents a major research challenge and will be critical in the development of effective therapeutic strategies. The recent development of experimental procedures that permit the stable germline transmission in mice (so-called transgenic mice) of specific genes with expression targeted to the intact CNS offers a powerful new approach for tackling this problem. In this paper we discuss our experience in the application of genetic engineering to develop transgenic mice with the astrocyte-targeted expression of the key mediators of the host response, the cytokines. Cytokines are a large family of pluripotent mediators with specific classes of these molecules being incriminated in the pathogenesis of inflammatory demyelinating diseases. Transgenic mice were developed in which the expression of the cytokines interleukin-6 or interleukin-3 was targeted to astrocytes using a glial fibrillary acidic protein genomic expression vector. Depending on which cytokine was expressed, these animals developed white matter disease with distinct patterns of demyelination associated with different pathologic features. Here we will describe the procedural details associated with the development of these transgenic models, focusing on three general themes: (i) production of transgenic animals, (ii) analysis of transgene expression, and (iii) characterization of the transgenic mouse phenotype.
 ...
PMID:Role of Cytokines in Demyelinating Disease Studied in Transgenic Mice 895 57

Astrocyte activation is a ubiquitous hallmark of the damaged brain and has been suggested to play an important regulatory role in the activation, survival, and regeneration of adjacent neurons, microglia, and oligodendrocytes. Little is known, however, about the endogenous signals that lead to this activation of astrocytes. Here we examined the regulation of interleukin 6 (IL6), a proinflammatory cytokine, its receptors, and the effects of IL6-deficiency in a model of traumatic central nervous system injury in the axotomized mouse facial motor nucleus. Facial nerve transection led to a massive but transient upregulation of IL6 mRNA in the disconnected motor nucleus, while IL6-receptor subunits were constitutively expressed on motoneurons and astrocytes. Absence of IL6 in genetically IL6-deficient mice led to massive reduction in the number of activated GFAP-positive astrocytes, a more moderate decrease in microglial activation and proliferation, and an increase in the late neuronal response to axotomy. These results emphasize the role of IL6 in the global regulation of neurons, astrocytes, and microglia and their activation in the injured nervous system.
 ...
PMID:Impaired neuroglial activation in interleukin-6 deficient mice. 906 29

In recent reports, ciliary neurotrophic factor (CNTF) has been implicated as an injury factor involved in regulating astrogliosis in the CNS. In this study, we used a rat oligodendroglial progenitor cell line that is highly responsive to CNTF to examine CNTF-induced alterations that may play a role in activation of the glial fibrillary acidic protein (GFAP) gene. We determined that CNTF induces the transient translocation of Stat1 alpha/p91 to the nucleus. This nuclear translocation was followed by GFAP promoter activation and an up-regulation of GFAP mRNA and protein. Level of CNTF-alpha receptor mRNA, however, were unaffected by addition of the ligand. Transfection studies using an upstream 5'-flanking, 1.9-kb rat GFAP promoter linked to a luciferase reporter gene revealed CNTF-induced transcriptional activation within 1 h of ligand exposure. Moreover, serial-deleted constructs identified a distal (-1,857 to -1,546 bp) and a proximal (-384 to -106 bp) region as being important for CNTF-induced GFAP promoter activation. These two regions showed a strong degree of overlap for CNTF- and serum-induced activation of the GFAP gene. Analysis of the two regions revealed several cis-elements that are thought to be involved in GFAP regulation and/or the regulation of other genes by members of the interleukin-6 family of cytokines. Moreover, we are the first to report the presence of several putative CNTF-responsive elements within our identified distal and proximal regions in the GFAP gene promoter.
 ...
PMID:Ciliary neurotrophic factor activates JAK/Stat signal transduction cascade and induces transcriptional expression of glial fibrillary acidic protein in glial cells. 908 11

Interleukin-6 (IL-6) and IL-6 receptor mRNA and protein have been reported in different brain regions under normal and pathophysiological conditions. Although much is known about the hypothalamic-pituitary-adrenal (HPA) axis stimulation after acute administration, less is known about the chronic effects of IL-6 on the function of the HPA axis. In the present study, we examined the function of the HPA axis in transgenic mice in which constitutive expression of IL-6 under the control of the glial fibrillary acidic protein (GFAP) promoter was targeted to astrocytes in the CNS. GFAP-IL6 mice heterozygous or homozygous for the IL-6 transgene had normal basal plasma corticosterone levels but, after restraint stress, showed abnormally increased levels in a gene dose-dependent manner. The increased plasma corticosterone levels in the IL-6 transgenic mice were associated with increased adrenal corticosterone content and hyperplasia of both adrenal cortex and medulla. Notably, plasma adrenocorticotrophic hormone (ACTH) levels and pituitary ACTH content were either not changed or decreased in these mice, whereas plasma arginine vasopressin (AVP) was increased, supporting a role for AVP in response to acute immobilization stress. The reduced ACTH response together with the adrenal hyperplasia in the IL-6 transgenic mice suggests direct activation at the level of the adrenal gland that may be directly activated by AVP or sensitized to ACTH. A similar mechanism may play a role in the blunted ACTH response and elevated corticosterone levels under pathophysiological conditions observed in humans with high brain levels of IL-6.
 ...
PMID:Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. 939 Oct 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>